|Bid||12.33 x 1200|
|Ask||12.35 x 2200|
|Day's Range||12.27 - 12.88|
|52 Week Range||5.20 - 19.90|
|Beta (5Y Monthly)||2.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.38|
Just because a business does not make any money, does not mean that the stock will go down. For example, Compugen...
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that management will present at the following upcoming virtual investor conferences:
With me from Compugen are Dr. Anat Cohen-Dayag, President and CEO; Dr. Henry Adewoye, Chief Medical Officer; Ari Krashin, CFO and COO; and Dr. Eran Ophir Field, VP, Research and Drug Discovery. Before we begin, I would like to read the following regarding forward-looking statements.